Main > ONCOLOGY (**) > Breast Cancer>HR+>HER2->MET *** > Treatment > CH. N. Ribociclib+ **



CH. N. Ribociclib+ **'s subsections
(*) CA Approval Date: 2020. 04.16.
(*) EU Approval Date: 2017. 08.24.
(*) USA Approval Date: 2017. 03.13.
+Letrozole (Aromatase Inhibitor)
CDK4/6 Inhibitor
Company
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 7
Patent>UpDate: 2020. 04.14.
TradeMark
TradeMark Web-Site

CH. N. Ribociclib+ **'s products
This section has no products